Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Nektar is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies. The company's primary asset is rezpegaldesleukin, an IL-2 receptor agonist being evaluated for autoimmune diseases including atopic dermatitis, alopecia areata, and Type 1 diabetes. The company also maintains a pipeline of TNFR2 agonists (NKTR-0165, NKTR-0166).
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $20,992 | $21,635 |
| Net Loss | $(85,526) | $(92,475) |
| Loss Per Share (Basic & Diluted) | $(2.96) | $(6.57) |
| Operating Cash Flow | $(120,068) | $(94,791) |
| Cash and Investments (Total) | $1,023,402 | $245,752 |
| Total Assets | $1,095,129 | $280,406 |
| Total Liabilities | $192,008 | $190,574 |
Note: Revenue consists entirely of non-cash royalty revenue related to the sale of future royalties. The company has no product sales revenue.
Material Changes vs. Prior Period
- Capital Position: Cash and investments increased significantly from $245.8 million to $1.02 billion, driven by equity financing transactions totaling $1.07 billion in net proceeds between July 2025 and April 2026.
- Operating Expenses: Research and Development (R&D) expenses increased 24% year-over-year to $74.8 million, primarily due to the initiation of Phase 3 ZENITH AD trials for rezpegaldesleukin. General and Administrative (G&A) expenses decreased 37% to $26.2 million, largely due to reduced legal costs.
- Net Loss Improvement: Net loss decreased by 8% to $85.5 million, despite higher R&D spend, due to a significant increase in interest income ($13.6 million vs. $4.8 million) resulting from higher cash balances.
- Share Count: Outstanding shares increased from approximately 20.4 million to 34.1 million due to multiple underwritten offerings and at-the-market (ATM) sales.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: In July 2026, the company initiated two global Phase 3 registrational trials (ZENITH AD-1 and ZENITH AD-2) for rezpegaldesleukin in atopic dermatitis. Phase 2b data for alopecia areata (REZOLVE-AA) showed statistical significance when excluding eligibility violations.
- Liquidity: Management believes current cash and investments are sufficient to fund operations for at least the next 12 months.
- Future Costs: R&D expenses are expected to increase significantly in the second half of 2026 to support Phase 3 trials and manufacturing activities.
Risks and Contingencies
- Litigation:
- Eli Lilly: A lawsuit regarding breach of contract is set for a jury trial on September 8, 2026. Lilly's counterclaims were dismissed.
- Securities Class Action: A putative class action (Schramke v. Nektar) was filed in March 2026 alleging misleading statements regarding the REZOLVE-AA trial. The company denies the claims.
- Indian GST: A demand for $3.3 million in tax refunds plus penalties is under appeal; no liability has been accrued.
- Supply Chain: The company is dependent on Gannet BioChem for the supply of PEG reagents used in manufacturing rezpegaldesleukin following the sale of its Huntsville facility.
- Regulatory: Risks include potential FDA delays due to government shutdowns or staffing issues, and the uncertainty of clinical trial outcomes.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $1.02 billion cash position against the projected burn rate for the Phase 3 ZENITH AD and AA programs.
- Dilution Impact: Assess the impact of the 67% increase in share count (from 20.4M to 34.1M shares) on future earnings per share.
- Revenue Quality: Confirm that the $21 million revenue is non-cash royalty revenue and does not represent operational cash generation.
- Litigation Exposure: Monitor the September 2026 trial date against Eli Lilly and the status of the securities class action regarding the REZOLVE-AA trial data.
- Manufacturing Dependency: Evaluate the risks associated with the single-source dependency on Gannet BioChem for critical PEG reagents.